• Explore /
  • Poster
  • / A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who are in second or third complete remission.

A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who are in second or third complete remission.

Abstract Poster

Authors

null

Paul Sabbatini

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

Paul Sabbatini , Lee-may Chen , Joseph A. Lucci , Kian Behbakht , Nicola M. Spirtos , Carolyn Muller , Benedict B. Benigno , Matthew A. Powell , Emily Berry , Krishnansu Sujata Tewari , Parviz Hanjani , Wei Deng , Heather A. Lankes , Carol Aghajanian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT00857545

Citation

J Clin Oncol 34, 2016 (suppl; abstr 5517)

DOI

10.1200/JCO.2016.34.15_suppl.5517

Abstract #

5517

Poster Bd #

340

Abstract Disclosures

Similar Posters

First Author: Agnieszka Michael

First Author: David M. O'Malley

First Author: JUNG-YUN LEE

First Author: Mansoor Raza Mirza